Therapy: Recommendations for the Oncologists

  • Francesco Facchinetti
  • Letizia Gnetti
  • Marcello Tiseo
Part of the Current Clinical Pathology book series (CCPATH)


Close collaboration between medical oncologist and other specialists is highly recommended in order to provide the best cures for patients affected by mediastinal tumors. Indeed, the medical oncologist often coordinates the multidisciplinary team involved in the diagnosis and treatment, this latter usually consisting in multimodality approaches. In the last years, immunotherapy and target agents have flanked chemotherapy in the systemic approach of the tumors arising in the mediastinum. Medical oncologist, besides being aware of their activity, should therefore give peculiar attention to the differential toxicities related to the old and new classes of drugs.


Multidisciplinary team Surgery Radiotherapy Chemotherapy Immunotherapy Targeted agents 


Conflict of Interest Declaration

All authors declare they have no conflict of interest to disclose.


  1. 1.
    Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2017. [Epub ahead of print].Google Scholar
  2. 2.
    Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.CrossRefGoogle Scholar
  3. 3.
    Waimey KE, Smith BM, Confino R, Jeruss JS, Pavone ME. Understanding fertility in young female cancer patients. J Women’s Heal. 2015;24:812–8.CrossRefGoogle Scholar
  4. 4.
    Harada M, Osuga Y. Where are oncofertility and fertility preservation treatments heading in 2016? Future Oncol. 2016;12:2313–21.CrossRefGoogle Scholar
  5. 5.
    Chuang S-C, Hashibe M, Scelo G, Brewster DH, Pukkala E, Friis S, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomark Prev. 2008;17:1543–9.CrossRefGoogle Scholar
  6. 6.
    Chen SC, Teng CJ, Hu YW, Yeh CM, Hung MH, Hu LY, et al. Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study. PLoS One. 2015;10:e0116384.CrossRefGoogle Scholar
  7. 7.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefGoogle Scholar
  8. 8.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefGoogle Scholar
  9. 9.
    Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol. 2017;8:37–53.CrossRefGoogle Scholar
  10. 10.
    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.CrossRefGoogle Scholar
  11. 11.
    Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–704.CrossRefGoogle Scholar
  12. 12.
    Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94.CrossRefGoogle Scholar
  13. 13.
    Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M. Moving immune checkpoint blockade in thoracic tumors beyond NSCLC. J Thorac Oncol. 2016;11:1819–36.CrossRefGoogle Scholar
  14. 14.
    Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. Idec-c2b8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–74.CrossRefGoogle Scholar
  15. 15.
    Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.CrossRefGoogle Scholar
  16. 16.
    Drilon A, Cappuzzo F, Ou SICD. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2017;12:15–26.CrossRefGoogle Scholar
  17. 17.
    Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177–86.CrossRefGoogle Scholar
  18. 18.
    Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Grellier L, et al. Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network. Lung Cancer. 2016;97:99–104.CrossRefGoogle Scholar
  19. 19.
    Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R, et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol. 2011;29:e803–5.CrossRefGoogle Scholar
  20. 20.
    Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.CrossRefGoogle Scholar
  21. 21.
    Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.CrossRefGoogle Scholar
  22. 22.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2017;36:7–13.CrossRefGoogle Scholar
  23. 23.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.CrossRefGoogle Scholar
  24. 24.
    Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984–93.CrossRefGoogle Scholar
  25. 25.
    Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559–74.CrossRefGoogle Scholar
  26. 26.
    Schramm N, Englhart E, Schlemmer M, Hittinger M, Übleis C, Becker CR, et al. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. Eur J Radiol. 2013;82:951–8.CrossRefGoogle Scholar
  27. 27.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRefGoogle Scholar
  28. 28.
    Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Francesco Facchinetti
    • 1
  • Letizia Gnetti
    • 2
  • Marcello Tiseo
    • 1
  1. 1.Medical Oncology UnitUniversity Hospital of ParmaParmaItaly
  2. 2.Pathology UnitUniversity Hospital of ParmaParmaItaly

Personalised recommendations